Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.
Top Regions
Top Stages
2 past transactions
TYME
Acquisition in 2022
Tyme Technologies, Inc. is a clinical-stage biotechnology company based in New York that specializes in developing cancer metabolism-based therapies (CMBTs). The company's lead candidate, SM-88, is undergoing Phase II/III clinical trials aimed at treating various cancers, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. Tyme Technologies also has a preclinical compound, TYME-18, targeting solid tumors. The company employs a unique approach that exploits the metabolic vulnerabilities of cancer cells, inducing cell death through oxidative stress and immune system activation. Tyme Technologies collaborates with notable institutions such as NYU Langone Health and Mayo Clinic to enhance treatment development for metastatic cancers. Founded in 2011, the company aims to commercialize therapeutics with broad efficacy and manageable toxicity profiles.
Orsenix
Acquisition in 2020
Orsenix is a clinical-stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other cancers. It is committed to transforming cancer treatment with innovative oral therapies that give patients the freedom to live their everyday lives.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.